Research Article

The Correlations of Plasma and Cerebrospinal Fluid Amyloid-Beta Levels with Platelet Count in Patients with Alzheimer’s Disease

Hao-Lun Sun, Wei-Wei Li, Chi Zhu, Wang-Sheng Jin, Yu-Hui Liu, Fan Zeng, Yan-Jiang Wang, and Xian-Le Bu

Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China

Correspondence should be addressed to Xian-Le Bu; buxianle@sina.cn

Received 21 June 2018; Accepted 30 September 2018; Published 15 October 2018

Academic Editor: Stavros Baloyannis

Copyright © 2018 Hao-Lun Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Recent study shows that blood-derived amyloid-beta (Aβ) can induce cerebral amyloidosis and is involved in the pathogenesis of Alzheimer’s disease (AD). The vast majority of blood Aβ is generated from platelet. Whether blood Aβ levels are associated with the count of platelets remains unknown. Methods. 58 clinically diagnosed AD patients, 18 11C-PIB-PET diagnosed AD patients, and 61 age- and gender-matched cognitively normal controls were included to analyze the correlation of plasma Aβ levels with platelet count. 13 AD patients and 40 controls with cerebrospinal fluid (CSF) samples were included to further analyze the correlation of CSF Aβ levels with platelet count. Aβ40 and Aβ42 levels in plasma and CSF were measured by ELISA kits. Results. The plasma Aβ42 level was positively correlated with platelet count in both AD patients and control group, especially in AD patients with positive PIB-PET, while there was no correlation as to Aβ40. The CSF Aβ42 levels also had no significant correlation with platelet count. Conclusion. It suggests that platelets may be involved in the pathogenesis of AD and become a potential peripheral biomarker for AD.

1. Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disorder in the elderly. It causes cognitive deficits and memory dysfunction that usually starts slowly and worsens over time. Amyloid-beta (Aβ) has been proven to play a crucial role in pathogenesis of AD. The vast majority of blood Aβ is generated from platelet. Whether blood Aβ levels are associated with the count of platelets remains unknown. Production and aggregation of the Aβ peptide give rise to the pathology of AD [1], and Aβ deposition in the brain parenchyma causes neuritic plaques, one of the neuropathological hallmarks of AD. Recent study has shown that blood Aβ could enter brain and lead to the occurrence of AD, suggesting that AD may be a systemic disease [2]. Platelets express amyloid precursor protein (APP), β-secretase, and γ-secretase, and thus it can generate Aβ [3, 4]. It has been shown that almost 90% of the blood Aβ originated from platelet [5]. Further, the activity of platelet membrane β-secretase in AD patients is significantly increased [6, 7]. Platelet activation may lead to the deposition of Aβ40 in the wall of brain vessels, which results in cerebral amyloid angiopathy (CAA) [8]. Thus, platelets are closely related to the pathogenesis of AD and may be a potential biomarker for early diagnosis of AD [9, 10]. However, there is a lack of clinical research on the relationship between platelets and Aβ. In the present study, we aim to investigate whether Aβ levels are correlated with the platelet count.

2. Methods

2.1. Study Population. AD patients were recruited from Chongqing Daping Hospital from May to December in 2017. Age- and gender-matched controls with normal cognition were randomly recruited from the hospitals during the same time. Subjects were excluded for the following reasons: (1) a family history of dementia; (2) a concomitant neurologic disorder that could potentially affect cognitive function or other types of dementia; (3) severe cardiac, pulmonary, hepatic, or renal diseases or any type of tumor; (4) enduring mental illness (e.g., schizophrenia); (5) hematological diseases or...
other diseases that could affect the number of platelets (e.g., essential thrombopenia); (6) use antiplatelet drugs recently (e.g., Aspirin). For the subjects with hypertension, their systolic blood pressure was controlled below 140 mmHg and the diastolic blood pressure was controlled below 90 mmHg by antihypertensive medication, such as captopril, valsartan, and nifedipine. As to diabetes, the fasting blood glucose was controlled between 5 and 7 mmol/L, and the postprandial blood glucose was controlled between 8 and 11 mmol/L by hypoglycemic agent (e.g., metformin, acarbose, and insulin). For the participants with hyperlipidemia, the blood low density lipoprotein ranges between 3.45 and 4.42 mmol/L, and some were given statins after evaluating against the balancing of risks and benefits of the medications. The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice, and it was approved by Institutional Review Board of Daping Hospital.

2.2. AD Diagnosis and Sampling. The clinical assessment and diagnosis of AD dementia were performed following the protocol we used before [11]. In brief, the demographic and medical history (such as hypertension, coronary heart disease, and diabetes mellitus) were collected. The cognitive and functional status were assessed based on a neuropsychological battery, and diagnosis of AD was made according to the criteria of National Institute of Neurological and Communicative Diseases and Stroke/AD and Related Disorders Association following the protocols we used before [11]. In addition, 18 people were administered with Aβ positron emission tomography (PET) inspection with Pittsburg compound B to detect and quantify Aβ deposition in the brain. Fasting blood was collected between 06:00 and 07:00 to avoid the potential circadian rhythm influence. The blood samples were centrifuged at once after sampled and then stored at −80 °C until use. Some participants underwent lumbar puncture (CON, n=40; AD, n=13) to obtain cerebrospinal fluid (CSF). The CSF samples were centrifuged at 2000g at 4°C for 10 min, and the aliquots were then immediately frozen and stored at −80 °C until use. The informed consent was obtained before the acquisition of the blood and CSF samples.

2.3. Measurements of Platelet and Aβ Levels. The count of platelet was measured using standard laboratory methods in the Clinical Laboratory, Daping Hospital, Chongqing, China. The human Aβ enzyme-linked immunosorbent assay (ELISA) kits (Invitrogen) were used to measure Aβ40 and Aβ42 levels in plasma and CSF. All of the ELISA measurements were performed in accordance with the manufacturers' instructions. All the samples and standards had received reduplicated measurements and statistical analyses.

2.4. Statistical Analysis. The differences in demographic characteristics, platelet count, and Aβ levels between the groups were assessed with two-tailed independent t-tests, Mann-Whitney U test, or Chi-square test as appropriate.

### 3. Results

#### 3.1. Characteristics of the Study Population. As shown in Table 1, the study consisted of 58 clinically diagnosed AD patients, 18 11C-PIB-PET diagnosed AD patients and 61 age- and gender-matched cognitively normal controls. AD patients and controls were similar in educational level (p1=0.225, p2=0.550), and there were no significant differences in the comorbidity of hypertension, diabetes mellitus, cardiovascular disease, and hyperlipidemia. No significant difference was found in the count of platelet between AD patients and controls (p1=0.478). AD patients with positive PIB-PET had slightly elevated platelets, but it was still not

|                | CON (n=61) | AD (n=58) | PIB-PET(+)–AD (n=18) | P1 value (AD vs. CON) | P2 value (PET vs. CON) |
|----------------|------------|-----------|----------------------|-----------------------|------------------------|
| **Age (years)**| 69.16±11.55| 71.52±10.71| 68.22±8.00           | 0.252                 | 0.748                  |
| **Female (%)** | 30 (49.18) | 30 (51.72) | 9 (50.00)            | 0.781                 | 0.951                  |
| **Education years** | 9.13±3.58  | 7.89±4.42  | 9.56±4.59            | 0.225                 | 0.550                  |
| **Hypertension (%)** | 14 (22.95) | 11 (18.97) | 3 (16.67)            | 0.594                 | 0.807                  |
| **Diabetes mellitus (%)** | 2 (3.28)  | 4 (6.90)  | 0                    | 0.629                 | >0.999                 |
| **Cardiovascular disease (%)** | 9 (14.75) | 5 (8.62)  | 1 (5.56)             | 0.299                 | 0.530                  |
| **Hyperlipidemia (%)** | 5 (8.20)  | 4 (6.90)  | 0                    | >0.999                | 0.481                  |
| **Platelet count** | 162.57±53.00 | 168.97±44.32 | 178.22±53.40 | <0.001                | <0.001                 |
| **MMSE**       | 27.17±2.75 | 16.48±6.51 | 12.17±5.76           | <0.001                | <0.001                 |
| **CDR**        | 0          | 1.86±0.86  | 2.08±0.88            | <0.001                | <0.001                 |

Table 1: Characteristics of the study population.

Data given as mean ± SD unless otherwise stated. MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating. P value, two-tailed independent t-tests, Mann-Whitney U test, or Chi-square test as appropriate.
3.2. Correlations of Plasma Aβ Levels with Platelet Count in AD Patients, Normal Controls, and All Cases. The AD patients had significant higher levels of both plasma Aβ40 (215.25±54.26 pg/ml versus 144.62±47.20 pg/ml, p<0.001) and Aβ42 (123.48±45.89 pg/ml versus 91.35±36.39 pg/ml, p<0.001) than the control group (Figure 1). There was no correlation between plasma Aβ40 level and platelet count in AD patients (γ=0.042, p=0.754), the controls (γ=0.103, p=0.430), or all cases (γ=0.097, p=0.293) (Figures 2(a), 2(c), and 2(e)), while plasma Aβ42 level had significantly positive correlation with platelet count in AD patients (γ=0.337, p=0.010), controls (γ=0.256, p=0.046), and all cases (γ=0.294, p=0.001) (Figures 2(b), 2(d), and 2(f)).

3.3. Correlation of Plasma Aβ42 Levels with Platelet Count in AD Patients with Positive PiB-PET. In order to test the findings further, we analyzed the correlation in PiB-PET positive AD patients. Just as shown in Figure 3(a), the plasma Aβ42 level was significantly increased in PiB-PET positive AD patients, and it was also positively correlated with platelet count (γ=0.521, p=0.027) (Figure 3(b)). These further indicate that blood Aβ42 levels may raise with the increase of platelet count.

3.4. Correlations of CSF Aβ Levels with Platelet Count in AD Patients and Normal Controls. Then CSF were collected from 13 AD patients and 40 age- and gender-matched controls to further analyze the correlation of CSF Aβ levels with platelet count. As shown in Supplemental Table 1, there were no significant differences in the comorbidity of hypertension, diabetes mellitus, cardiovascular disease, and hyperlipidemia between two groups. Platelet counts also showed no difference. The CSF Aβ40 (5.88±2.29 ng/ml versus 12.87±3.18 ng/ml, p<0.001) and Aβ42 (449.58±163.69 pg/ml versus 1212.17±285.09 pg/ml, p<0.001) levels were significantly decreased in AD patients (Supplemental Figure 1). However, there were no correlations of CSF Aβ40 or Aβ42 levels with platelet count in either AD or control group (Figure 4).

4. Discussion

To our knowledge, this is the first research to investigate the association between plasma and CSF Aβ levels and platelet count. In this study, we found that the blood Aβ42 levels were positively correlated with platelet count, especially in AD patients with positive PiB-PET, while there was no significant correlation of blood Aβ40 or CSF Aβ levels with platelet count.

According to the previous point of view, brain Aβ is primarily produced by the transmembrane glycoprotein APP in neuron. Platelets, containing β- and γ-secretase, are the main peripheral source of APP protein and can generate Aβ in a mechanism similar to neurons [12, 13]. It is estimated that nearly 90% of blood Aβ is generated from platelets, which is mainly Aβ40 [5]. However, whether blood Aβ levels are associated with platelet count remains unknown. In this study, we further found a positive correlation between blood Aβ42 levels and platelet count, which is consistent with previous view platelet being the primary source of Aβ.

The lack of correlation between CSF Aβ levels and platelet count indicates that platelet count may not affect brain Aβ burden. The significant association between plasma Aβ levels and platelet count implies that platelet count may be not only

![Figure 1: Comparison of the plasma Aβ levels between the controls and patients with AD. * * * denotes p<0.001.](image-url)
involved in peripheral Aβ production but also in peripheral Aβ clearance. It has been shown that platelets regulate soluble Aβ into fibrillar structures by the absorption of apoptotic platelets [14] which leads to platelet activation and adhesion that also mediates the occurrence and development of cerebral amyloid angiopathy (CAA), which is common in AD. It is still not certain of why plasma Aβ42 but not Aβ40 was correlated with platelet count, but we think there are several possible reasons. One possible explanation is that Aβ40 is more readily degraded by plasma proteases such as insulin-degrading enzyme, neprilysin, angiotensin-converting enzyme, and metalloproteases that are abundant...
**Figure 3:** Correlation of plasma $A\beta_{42}$ levels with platelet count in AD patients with PiB-PET (+). * denotes $p < 0.05$.

**Figure 4:** Correlations of CSF $A\beta$ levels with platelet count in AD patients ((a) and (b)) and normal controls ((c) and (d)).
in the blood circulation [15]. Aβ42 is more resistant to degradation because it is more aggregating and adhesive. Additionally, increased platelet count may make Aβ42 more difficult to be cleared in the periphery [16]. Activated platelets also make Aβ42 resistant to be degraded [6]. Therefore, there is a positive correlation of plasma Aβ42 level with the number of platelets.

Previous studies also showed that the membrane β-secretase activity of platelet is increased by 24% in patients with mild cognitive impairment and by 17% in those with AD [6, 17, 18]. Therefore, the dysfunctions of APP metabolism might be a systemic problem in AD. There is no significant difference in the count of platelet between AD and normal control group. However, AD patients with positive PIB-PET tend to have increased platelet count. The increased activity of platelet β-secretase in AD patients could lead to the overproduction of Aβ, which is probably responsible for the higher blood Aβ levels in AD. It has been generally accepted that Aβ deposited in the brain originates from the brain tissue itself. However, our recent study proved that blood Aβ is capable of crossing the blood-brain barrier and inducing AD-type pathologies [2]. Since platelets contribute to the mainly blood Aβ. It is probably that the Aβ derived from platelet is contributory to AD pathogenesis.

This study implies that platelet may play a role in the pathogenesis of AD, which further indicates that AD is a systemic disease. Whether the disorders increasing platelet activity or platelet count could raise AD risk deserves further investigation. Notability, this is an observational study that we cannot determine the effect of platelets count and Aβ levels on AD progression. Longitudinal studies are needed to better clarify the impact of the dynamic changes of platelets and Aβ on AD in the future. In addition, we need to increase the number of AD patients with positive PIB-PET to better verify the difference in platelet count between AD and the controls.

In conclusion, our study showed that blood Aβ42 level was positively correlated with platelet count. It suggests that platelets may be involved in the pathogenesis of AD and become a potential biomarker for AD.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon reasonable request.

**Conflicts of Interest**

The authors declare no financial or other conflicts of interest.

**Acknowledgments**

This study was supported by the National Key R & D Program of China (2018YFA0109600) and the National Natural Science Foundation of China (Grant no. 81701043).

**Supplementary Materials**

Supplemental Table 1 showed the characteristics of the participants with CSF samples. Supplemental Figure 1 showed the CSF Aβ levels of the controls and patients with AD. (Supplementary Materials)

**References**

[1] Y. Huang and L. Mucke, "Alzheimer mechanisms and therapeutic strategies," *Cell*, vol. 148, no. 6, pp. 1204–1222, 2012.

[2] X. Bu, Y. Xiang, W. Jin et al., “Blood-derived amyloid-β protein induces Alzheimer’s disease pathologies,” *Molecular Psychiatry*, 2017.

[3] F. Colciaghi, E. Marcello, B. Borroni et al., “Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease,” *Neurology*, vol. 62, no. 3, pp. 498–501, 2004.

[4] Y. Shi, L. Gu, A. A. Alsharif, and Z. Zhang, “The Distinction of Amyloid-β Protein Precursor (AβPP) Ratio in Platelet between Alzheimer’s Disease Patients and Controls: A Systematic Review and Meta-Analysis,” *Journal of Alzheimer’s Disease*, vol. 59, no. 3, pp. 1037–1044, 2017.

[5] M. Chen, N. C. Inestrosa, G. S Ross, and H. L. Fernandez, *Platelets Are the Primary Source of Amyloid β-Peptide in Human Blood*, 1995.

[6] J. Johnston, W. Liu, D. Coulson et al., “Platelet β-secretase activity is increased in Alzheimer’s disease,” *Neurobiology of Aging*, vol. 29, no. 5, pp. 661–668, 2008.

[7] B. McGuinness, M. Fuchs, S. L. Barrett, A. P. Passmore, and J. A. Johnston, “Platelet membrane β-secretase activity in mild cognitive impairment and conversion to dementia: A longitudinal study,” *Journal of Alzheimer’s Disease*, vol. 49, no. 4, pp. 1095–1103, 2015.

[8] W. Zhang, H. Huang, and F. Jing, “Contribution of blood platelets to vascular pathology in Alzheimer’s disease,” *Journal of Blood Medicine*, p. 141.

[9] M. Veitinger, B. Varga, S. B. Guterres, and M. Zellner, ”Platelets, a reliable source for peripheral Alzheimer’s disease biomarkers,” *Acta Neuropathologica Communications*, vol. 2, no. 1, 2014.

[10] O. E. Akingbade, C. Gibson, R. N. Kalaria, and E. B. Mukaetova-Ladinska, "Platelets: Peripheral Biomarkers of Dementia?" *Journal of Alzheimer’s Disease*, vol. 63, no. 4, pp. 1235–1259, 2018.

[11] J. Li, Y. J. Wang, M. Zhang et al., “Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease,” *Neurology*, vol. 76, no. 17, pp. 1485–1491, 2011.

[12] Q.-X. Li, G. Evin, D. H. Small, G. Multhaup, K. Beyreuther, and C. L. Masters, "Proteolytic processing of Alzheimer’s disease βA4 amyloid precursor protein in human platelets," *The Journal of Biological Chemistry*, vol. 270, no. 23, pp. 14140–14147, 1995.

[13] G. Evin, A. Zhu, R. M. D. Holsinger, C. L. Masters, and Q.-X. Li, "Proteolytic Processing of the Alzheimer’s Disease Amyloid Precursor Protein in Brain and Platelets," *Journal of Neuroscience Research*, vol. 74, no. 3, pp. 386–392, 2003.

[14] N. S. Gowert, L. Donner, M. Chatterjee et al., "Blood platelets in the progression of Alzheimer’s disease," *PLoS ONE*, vol. 9, no. 2, Article ID e90523, pp. 1–16, 2014.

[15] R. J. Baranello, K. L. Bharani, V. Padmaraju et al., "Amyloid-beta protein clearance and degradation (ABCD) pathways and their
role in Alzheimer’s disease,” Current Alzheimer Research, vol. 12, no. 1, pp. 32–46, 2015.
[16] J. M. Tarasoff-Conway, R. O. Carare, R. S. Osorio et al., “Clearance systems in the brain-implications for Alzheimer disease,” Nat Rev Neurol, vol. 1, pp. 457–470, 2015.
[17] W. Liu, S. Todd, D. Craig et al., “Elevated Platelet β-Secretase Activity in Mild Cognitive Impairment,” Dementia and Geriatric Cognitive Disorders, vol. 24, no. 6, pp. 464–468, 2007.
[18] P. Bermejo-Bescós, S. Martín-Aragón, K. Jiménez-Aliaga et al., “Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI),” Neurochemical Research, vol. 38, no. 7, pp. 1415–1423, 2013.